Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FOXO Technologies sits at the crossroads of epigenetics and life insurance, so its SEC filings blend biotech R&D language with actuarial detail. For analysts trying to track patent milestones alongside reinsurance agreements, parsing a 300-page 10-K can feel overwhelming. Questions like “where do I see FOXO insider trading Form 4 transactions?” or “how is DNA-methylation research funded this quarter?” quickly surface. That complexity is why many investors start their research here.
Stock Titan’s AI reads every FOXO quarterly earnings report 10-Q filing the moment it hits EDGAR and distills the revenue shifts, cash-burn trends, and regulatory notes into plain English. Need a quick brief? Our platform flags FOXO 8-K material events explained in under 90 seconds, delivers FOXO Form 4 insider transactions real-time, and links each data point to the original PDF. You’ll also find an AI walkthrough that makes the FOXO annual report 10-K simplified, complete with section-by-section jump links. No more skimming footnotes to understand deferred R&D tax credits or goodwill tests—our expert analysis highlights them for you.
Because FOXO is pioneering longevity underwriting, its proxy statement executive compensation tables reveal how management is incentivized to hit biomarker validation goals, while the FOXO earnings report filing analysis shows progress on lab commercialization. You can monitor FOXO executive stock transactions Form 4 before capital raises, compare cohort survival models across filings, and export the numbers for your own models. Whether you’re focused on understanding FOXO SEC documents with AI or just need a single ratio for tomorrow’s pitch, every disclosure is indexed, searchable, and continuously updated. Explore the complete FOXO library—10-K, 10-Q, 8-K, S-1, and more—FOXO SEC filings explained simply.
FOXO Technologies, Inc. reported continued operating losses and liquidity strain for the six months ended June 30, 2025. The company had a working capital deficit of $27.3 million and only $0.3 million of cash and cash equivalents at June 30, 2025. Cash used in operating activities for the six months was $3.7 million. Total debt, net of discounts, was $11.2 million and total stockholders' equity was $13.7 million. Goodwill increased to approximately $31.3 million. The healthcare segment recorded meaningful changes in recognized net revenues after estimating contractual allowances: healthcare net revenues were $5.2 million for the three months and $8.4 million for the six months ended June 30, 2025, compared with minimal prior-year amounts. The period included material financing and capital-structure events, including exchanges of Senior PIK Notes into Series B Preferred Stock and the issuance of Series A Preferred Stock (3,400 shares for gross proceeds of $3.35 million). The filing discloses multiple notes and defaults, related-party balances, accrued liabilities including severance of $2.17 million, and legal/settlement items. Management disclosed ongoing discussions with creditors on extensions and various subsequent conversions and exchanges of preferred stock into common shares.
FOXO Technologies Inc. reports material balance sheet and financing activity tied to 2024 acquisitions and debt restructurings. The company had a working capital deficit of $30.6 million and only $16,907 in cash and cash equivalents as of March 31, 2025. For the three months ended March 31, 2025, FOXO reported a net loss attributable to common stockholders of $788,583, or $0.73 per Class A share; comparable prior-period weighted average shares and loss per share are shown in the filing.
The company recorded a $1.86 million gain from extinguishment of Senior PIK Notes after exchanging those notes into Series B Preferred Stock. Healthcare net revenues for the quarter were $3.2 million after estimated contractual allowances. Total debt (net of discounts) was $6.0 million with multiple notes and related-party payables disclosed, several in default or subject to negotiation; goodwill of approximately $25.5 million relates to the Myrtle and RCHI acquisitions and additional purchase-price contingencies remain within the one-year measurement period.
FOXO Technologies, Inc. filed an 8-K disclosing an Item 3.01 event and partial transaction details for the purchase of RCHI. The filing lists tangible assets acquired of $14,274,919 and shows a payable of $5,132,928 described as "Payable to RHI for purchase of RCHI."
The document also displays asset line items including Goodwill $25,463,948 and a combined current liabilities figure of $6,974,811 (with $1,841,883 shown separately). The filing appears focused on the acquisition accounting presentation and discloses commitments and contingencies but is fragmentary and lacks complete narrative context or transaction terms.
FAQ
What is the current stock price of FOXO TECHNOLOGIES (FOXO)?
What is the market cap of FOXO TECHNOLOGIES (FOXO)?
